ADAR1 Capital Management

ADAR1 Capital Management, founded in October 2018 by Dr. Daniel Schneeberger, is an SEC-registered investment manager based in Austin, Texas. The firm specializes in public and private equity investments within the life sciences and biotechnology sectors. Dr. Schneeberger brings over 20 years of experience spanning scientific research, healthcare consulting, institutional investing, and executive leadership in the healthcare industry. He is supported by a team of professionals with deep medical and scientific expertise and a strong track record in biopharmaceutical investing. The firm's investment strategy emphasizes long-term growth and value creation, particularly in sectors with high potential for innovation and development. ADAR1 Capital Management has been actively involved in shareholder activism, notably engaging with Keros Therapeutics to influence its capital allocation and governance decisions. The firm has also made significant investments in companies such as Inhibikase Therapeutics Inc., reflecting its commitment to the healthcare sector. With assets under management totaling approximately $819.9 million as of March 31, 2025, ADAR1 Capital Management continues to focus on strategic investments that align with its expertise and investment philosophy.